What is Aurobindo Pharma Limited (AUROPHARMA) share price today?

Aurobindo Pharma Limited (AUROPHARMA) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/AUROPHARMA for the latest live price, technical analysis, and AI-powered insights.

How to analyse AUROPHARMA stock?

VestAI provides comprehensive AUROPHARMA stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Aurobindo Pharma Limited in?

Aurobindo Pharma Limited (AUROPHARMA) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Aurobindo Pharma Limited

Q: What is Aurobindo Pharma Limited's Orion Score?

Aurobindo Pharma Limited has an Orion Score of 52/100 (Watch) — a fundamentals-based quality & risk score. Aurobindo Pharma Limited scores 52/100 (Watch) on the Orion Score — moderate business quality (51), weak growth (41), strong balance-sheet safety (77) and rich valuation (39). A fundamentals-based quality & risk score, not a buy/sell recommendation.

AUROPHARMA

NSE· Healthcare

₹1,549.30

-15.40 (-0.98%)

Updated 12:35 pm IST

52W Low · ₹1,016.1052W High · ₹1,636.80

Near 52W High

Market Cap

₹90029.38L Cr

Volume

7.36L

Prev Close

₹1,564.70

ISIN

INE406A01037

Orion Score

Fundamentals-based quality & risk · not a recommendation

52/100

Watch

Aurobindo Pharma Limited scores 52/100 (Watch) on the Orion Score — moderate business quality (51), weak growth (41), strong balance-sheet safety (77) and rich valuation (39). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Profit converts to cash (CFO 0.6× PAT)
Low debt, comfortable interest cover
No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 5/9Altman Z Safe(7.57)Beneish M Clean(-2.35)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

68/100

Strong

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.21x — lean balance sheet

QUALITY

Average

ROCE 12.6% — decent returns

MOMENTUM

Neutral

RSI 56.3 — consolidating

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio: 25.94
ROCE: 12.55%
ROE (1Y): 9.93%
D/E Ratio: 0.21x
OPM: 15.11%
TTM EPS: ₹60.32
Dividend Yield: 25.00%
Qtrly Sales: ₹8,751.50 Cr
Qtrly Profit: ₹921.26 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q4 2026	₹8,751.5	₹921.26	15.1%	₹15.86
Q3 2026	₹8,604.51	₹910.29	15.2%	₹15.67
Q1 2026	₹7,791.77	₹824.75	15.4%	₹14.20
Q4 2025	₹8,381.12	₹903.47	16.1%	₹15.56
Q3 2025	₹7,893.15	₹845.81	15.3%	₹14.56

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2025	₹31,378.13	₹3,485.88	₹7,097.88	16.1%
FY 2024	₹28,704.5	₹3,172.97	₹6,139.99	15.5%
FY 2023	₹24,617.13	₹1,927.5	₹3,986.03	10.3%
FY 2022	₹23,366.55	₹2,648.15	₹4,536.1	14.1%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
AUROPHARMA ★	₹90,029 Cr	25.94	12.55%	9.93%	0.21x	15.11%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
CIPLACipla Limited	₹1,16,281 Cr	29.99	13.66%	11.74%	0.02x	9.50%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
ABBOTINDIAAbbott India Limited	₹57,724 Cr	36.63	36.14%	34.46%	0.04x	27.01%
AJANTPHARMAjanta Pharma Limited	₹41,836 Cr	39.55	27.99%	25.39%	0.06x	51.40%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹49,784.97	₹45,071.51	₹39,889.99	₹33,921.72
Equity	₹32,653.32	₹29,842.8	₹26,839.85	₹24,575.98
Total Debt	₹8,262.87	₹6,647.63	₹5,286.21	₹3,278.96
Cash	₹5,568.95	₹3,393.48	₹4,396.29	₹4,162.51
Net Debt	₹2,372.73	₹2,921.74	₹465.23	—
Working Capital	₹12,480.12	₹12,006.5	₹10,051.89	₹9,966.71

Shareholding Pattern

Q1 FY2027

Promoter

54.83%

FII

16.84%

DII

13.77%

Public

14.56%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	54.83% ↑	16.84% ↑	13.77% ↑	14.56% ↓
Q4 FY2026	54.2% ↑	15.84% ↑	12.96% ↓	17% ↑
Q3 FY2026	51.82%	13.95% ↓	27.66% ↑	6.55% ↑
Q2 FY2026	51.82%	14.21% ↓	27.6% ↑	6.37% ↓
Q1 FY2026	51.82%	14.38% ↓	26.93% ↑	6.88% ↑
Q4 FY2025	51.82%	15.33% ↓	26.23% ↑	6.61% ↓
Q3 FY2025	51.82%	16.29% ↓	25.21% ↑	6.67% ↑
Q2 FY2025	51.82%	16.59%	25.14%	6.45%

Corporate Actions

Ex-Date	Action	Details
2026-04-17	BUYBACK	Buy Back

Funds Holding This Stock

194 mutual fund schemes

Quant Mid Cap Fund Direct GrowthESCORTS

9.44%

₹766 Cr

Quant Manufacturing Fund Direct GrowthESCORTS

8.51%

₹60 Cr

Quant Large and Mid Cap Fund Direct GrowthESCORTS

8.23%

₹282 Cr

Quant Business Cycle Fund Direct GrowthESCORTS

8.09%

₹82 Cr

Quant Multi Cap Fund Direct GrowthESCORTS

7.92%

₹607 Cr

Quant Dynamic Asset Allocation Fund Direct GrowthESCORTS

7.68%

₹71 Cr

Quant Momentum Fund Direct GrowthESCORTS

7.43%

₹101 Cr

Quant ELSS Tax Saver Fund Direct GrowthESCORTS

7.26%

₹949 Cr

Quant Aggressive Hybrid Fund Direct GrowthESCORTS

6.79%

₹144 Cr

Tata Nifty MidSmall Healthcare Index Fund Direct GrowthTATA

6.64%

₹11 Cr

Analyse AUROPHARMA with Orion AI

Ask: "Is Aurobindo Pharma Limited stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Aurobindo Pharma Limited (AUROPHARMA) Stock

Aurobindo Pharma Limited is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE406A01037. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.